Agnuside | CAS:11027-63-7 | Manufacturer ChemFaces

Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.

Biomed Pharmacother.2024, 176:116765.

Int Immunopharmacol.2022, 106:108603.

J Ethnopharmacol.2019, 228:132-141

Food and Agriculture Org. Of the UN2019, 151-160

Arch Toxicol.2024, 98(5):1415-1436.

Sci Rep.2019, 9:19059

Mol Med Rep.2024, 29(2):26.

International Food Research Journal2018, 25(6):2560-2571

Front Neurosci.2019, 13:1091

J Ethnopharmacol.2024, 335:118628.

Inflamm Res. 2012 Apr;61(4):293-304.

Anti-arthritic activity of agnuside mediated through the down-regulation of inflammatory mediators and cytokines.[Pubmed: 22228102]

The purpose of this study was to elucidate the probable mechanism for the anti-arthritic activity of Agnuside (AGN), a compound isolated from the leaf extract of Vitex negundo.
METHODS AND RESULTS:
The anti-inflammatory activity of AGN within a dose range of 1.56-12.50 mg/kg in normal and adrenalectomized rats was evaluated against different inflammagens. An array of pro-inflammatory mediators (PGE(2) and LTB(4)) and T-cell-mediated cytokines (IL-2, TNF-α, IFN-γ, IL-4, IL-10, IL-17) was assayed using flow cytometry, in arthritic paw tissue homogenate and splenocytes of treated animals. Significant anti-arthritic activity was observed in the polyarthritis test in rats and this was associated with significant suppression of inflammatory mediators and T-cell-mediated cytokines (Th1/Th2). The anti-inflammatory activity in adrenalectomized rats confirmed that the effect of AGN is not mediated by the pituitary-adrenal axis. AGN also showed inhibition of vascular permeability and leukocyte migration in vivo.
CONCLUSIONS:
The study suggests the possible development of AGN as a therapeutic agent in the treatment of arthritis by the modulation of the host immune response.

Inflamm Res. 2012 Apr;61(4):293-304.

Anti-arthritic activity of agnuside mediated through the down-regulation of inflammatory mediators and cytokines.[Pubmed: 22228102]

Animal Models: Fourteen-week-old Wistar rats (150–180 g) and 12-weekold Swiss albino mice (24–30 g)
Formulation: A suspension in gumacacia (1% w/v)
Dosages: 1.56, 3.12, 6.25, 12.50 mg/kg
Administration: p.o.

Product Name	Agnuside
CAS No.:	11027-63-7
Catalog No.:	CFN99203
Molecular Formula:	C₂₂H₂₆O₁₁
Molecular Weight:	466.4 g/mol
Purity:	>=98%
Type of Compound:	Iridoids
Physical Desc.:	Powder
Targets:	TNF-α \| PGE \| LTB \| IL Receptor \| IFN-γ
Source:	The herbs of Vitex negundo L.
Solvent:	DMSO, Pyridine, Methanol, Ethanol, etc.
Price:	$168/20mg